COVID-19 has accounted for more than 6 million deaths worldwide. Bacillus Calmette–Guérin (BCG), the existing tuberculosis vaccine, is known to induce heterologous effects over other infections due to trained immunity and has been proposed to be a potential strategy against SARS-CoV-2 infection. In this report, we constructed a recombinant BCG (rBCG) expressing domains of the SARS-CoV-2 nucleocapsid and spike proteins (termed rBCG-ChD6), recognized as major candidates for vaccine development. We investigated whether rBCG-ChD6 immunization followed by a boost with the recombinant nucleocapsid and spike chimera (rChimera), together with alum, provided protection against SARS-CoV-2 infection in K18-hACE2 mice. A single dose of rBCG-ChD6 boosted with rChimera associated with alum elicited the highest anti-Chimera total IgG and IgG2c Ab titers with neutralizing activity against SARS-CoV-2 Wuhan strain when compared with control groups. Importantly, following SARS-CoV-2 challenge, this vaccination regimen induced IFN-γ and IL-6 production in spleen cells and reduced viral load in the lungs. In addition, no viable virus was detected in mice immunized with rBCG-ChD6 boosted with rChimera, which was associated with decreased lung pathology when compared with BCG WT-rChimera/alum or rChimera/alum control groups. Overall, our study demonstrates the potential of a prime-boost immunization system based on an rBCG expressing a chimeric protein derived from SARS-CoV-2 to protect mice against viral challenge.

TheSchistosoma mansoni SmKI-1 protein is composed of two domains: a Kunitz-type serine protease inhibitor motif (KD) and a C-terminus domain with no similarity outside the genera. Our previous work has demonstrated that KD plays an essential role in neutrophil elastase (NE) binding blockage, in neutrophil influx and as a potential anti-inflammatory molecule. In order to enhance NE blocking capacity, we analyzed the KD sequence from a structure-function point of view and designed specific point mutations in order to enhance NE affinity. We substituted the P1 site residue at the reactive site for a leucine (termed RL-KD), given its central role for KD’s inhibition to NE. We have also substituted a glutamic acid that strongly interacts with the P1 residue for an alanine, to help KD to be buried on NE S1 site (termed EA-KD). KD and the mutant proteins were evaluatedin silicoby molecular docking to human NE, expressed inEscherichia coliand tested towards its NE inhibitory activity. Both mutated proteins presented enhanced NE inhibitory activityin vitroand RL-KD presented the best performance. We further tested RL-KDin vivoin an experimental model of monosodium urate (MSU)-induced acute arthritis. RL-KD showed reduced numbers of total cells and neutrophils in the mouse knee cavity when compared to KD. Nevertheless, both RL-KD and KD reduced mice hypernociception in a similar fashion. In summary, our results demonstrated that both mutated proteins showed enhanced NE inhibitory activityin vitro. However, RL-KD had a prominent effect in diminishing inflammatory parametersin vivo.

Human alphaherpesvirus 1 (HSV-1) is a significantly widespread viral pathogen causing recurrent infections that are currently incurable despite available treatment protocols. Studies have highlighted the potential of antimicrobial peptides sourced from Vespula lewisii venom, particularly those belonging to the mastoparan family, as effective against HSV-1. This study aimed to demonstrate the antiviral properties of mastoparans, including mastoparan-L [I⁵, R⁸], mastoparan-MO, and [I⁵, R⁸] mastoparan, against HSV-1. Initially, Vero cell viability was assessed in the presence of these peptides, followed by the determination of antiviral activity, mechanism of action, and dose-response curves through plaque assays. Structural analyses via circular dichroism and nuclear magnetic resonance were conducted, along with evaluating membrane fluidity changes induced by [I⁵, R⁸] mastoparan using fluorescence-labeled lipid vesicles. Cytotoxic assays revealed high cell viability (>80%) at concentrations of 200 µg/mL for mastoparan-L and mastoparan-MO and 50 µg/mL for [I⁵, R⁸] mastoparan. Mastoparan-MO and [I⁵, R⁸] mastoparan exhibited over 80% HSV-1 inhibition, with up to 99% viral replication inhibition, particularly in the early infection stages. Structural analysis indicated an α-helical structure for [I⁵, R⁸] mastoparan, suggesting effective viral particle disruption before cell attachment. Mastoparans present promising prospects for HSV-1 infection control, although further investigation into their mechanisms is warranted.

Introns are removed from mRNAs by the spliceosome, a type of protein-RNA machinery enriched with intrinsically disordered regions (IDRs). Lacking stable 3D structures, IDRs can adopt diverse conformations interlacing protein and RNA components of the spliceosome and regulating splicing. In this work, we performed a comprehensive bioinformatics analysis of the human spliceosome proteome, revealing that many proteins contain more than 40% disordered residues. Spliceosome IDRs are mainly driven by compositional bias due to an excess of charged and RS-like sequences, with the nature and extent of this disorder being broadly conserved evolutionarily. Additionally, these IDRs are frequent targets of post-translational modifications, especially phosphorylation, and are hot spots for cancer-associated mutations, which have been implicated in different types of cancer. Our results collectively underscore the central role of IDRs in splicing regulation and disease.

Introns are removed from messenger RNAs by the spliceosome, a protein-RNA machinery enriched with intrinsically disordered regions (IDRs). Lacking stable 3D structures, IDRs can adopt diverse conformations interlacing proteins and RNAs components of the spliceosome and regulating splicing. Here we performed a comprehensive bioinformatics analysis of the human spliceosome proteome revealing that many proteins contain over 40% of disordered residues. Spliceosome IDRs are mainly driven by compositional bias due to an excess of charged and RS-like sequences, with both the nature and extent of this disorder being broadly conserved evolutionarily. Additionally, these IDRs are frequent targets of post-translational modifications, especially phosphorylation, and are hotspots for cancer-associated mutations, implicated in different cancer types. Our results collectively underscore central role of IDRs in splicing regulation and disease. TOC Graphic: